Akebia Therapeutics Inc (FRA:AX9)
€ 1.642 0.149 (9.98%) Market Cap: 359.71 Mil Enterprise Value: 368.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Q3 2020 Akebia Therapeutics Inc Earnings Call Transcript

Nov 05, 2020 / 02:00PM GMT
Release Date Price: €2.16 (+4.85%)
Operator

Good day, ladies and gentlemen, and welcome to Akebia Therapeutics Third Quarter Fiscal 2020 Financial Results and Business Update Conference Call. As a reminder, this call is being recorded. I would now like to introduce your host for today's event, Kristen Sheppard, Senior Vice President of Investor Relations with Akebia.

Kristen K. Sheppard
Akebia Therapeutics, Inc. - VP of IR

Thank you, and welcome to Akebia's Third Quarter Fiscal 2020 Financial Results and Business Update Conference Call. Please note that the press release detailing our results for the third quarter was issued earlier this morning and is available on our Investor Relations website. For your convenience, a replay of today's call will also be available on our website shortly after we conclude today's call.

Joining me for today's call is John Butler, our Chief Executive Officer; and David Spellman, our Chief Financial Officer.

Before we begin, I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement contained in this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot